Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

Synthetic Lethality Oncology Company Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss. Vopimetostat Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen...

Recent company news

TNGXTango Therapeutics2026-08-11 11:00 EST

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

TNGXTango Therapeutics2026-08-06 22:24 EST

Tango Therapeutics Announces Proposed $500 Million Public Offering

Stock data

Close: 23.88 USD
Market cap: 3.11B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

Related news

Tango Therapeutics Announces Executive Chair Transition

Tango Therapeutics Appoints Robert Azelby to Board of Directors

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Regeneron Announces Investor Conference Presentations

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

Tango Therapeutics